TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38215546

Group type: EXPERIMENTAL
Intervention: Avasopasem manganese (AVA)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Cisplatin
Number of subjects: 2
Study: 38215598

Group type: EXPERIMENTAL
Intervention: Radiolabeled perfusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Water evaluation
Number of subjects: 0
Study: 38215770

Group type: EXPERIMENTAL
Intervention: De-escalation to narrower-spectrum antibiotics (ampicillin, trimethoprim-sulfamethoxazole, cefuroxime, cefotaxime, ceftriaxone, amoxicillin-clavulanic acid, ciprofloxacin, or ertapenem)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Continue with empiric antipseudomonal β-lactam
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: De-escalation group
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 344
Study: 38215808

Group type: EXPERIMENTAL
Intervention: AI-DED (Artificial intelligence-adjudicated dispersion extent and distribution)
Number of subjects: 78
Study: 38215876

Group type: EXPERIMENTAL
Intervention: Observational Cohort (OBS)
Number of subjects: 2250

Group type: COMPARATOR
Intervention: Randomized Clinical Trial (RCT)
Number of subjects: 2250
Study: 38215886

Group type: EXPERIMENTAL
Intervention: Ketone monoester
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Whey protein (10 g)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Co-ingestion of ketone monoester and whey protein
Number of subjects: 36
Study: 38215932

Group type: EXPERIMENTAL
Intervention: Omecamtiv mecarbil
Number of subjects: 8256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8256
Study: 38215973

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) added to furosemide
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo added to furosemide
Number of subjects: 230
Study: 38216022

Group type: EXPERIMENTAL
Intervention: Adalimumab responders
Number of subjects: 1515

Group type: COMPARATOR
Intervention: Adalimumab nonresponders
Number of subjects: 1515
Study: 38216183

Group type: EXPERIMENTAL
Intervention: Optimise longitudinal cohort and qualitative interviews
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Monthly quantitative surveys and daily diaries
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Qualitative interviews at key time points
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Community engagement groups
Number of subjects: 1000
Study: 38216189

Group type: EXPERIMENTAL
Intervention: AF screening enrichment using a risk prediction model (RPM) followed by 14 days of a continuous ECG patch
Number of subjects: 740

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Groups enriched by the RPM
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: Groups without invitation to 14 days of continuous ECG recording
Number of subjects: 740

Group type: EXPERIMENTAL
Intervention: All four groups
Number of subjects: 740
Study: 38216192

Group type: EXPERIMENTAL
Intervention: Decentralised trial models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrification of sponsor vehicle fleets
Number of subjects: 0
Study: 38216198

Group type: EXPERIMENTAL
Intervention: Interruptive alert for oral fluid restriction in patients treated with intravenous furosemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38216200

Group type: EXPERIMENTAL
Intervention: Green tea extract (1650 mg daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 200
Study: 38216290

Group type: EXPERIMENTAL
Intervention: RAID questionnaire
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Patient global assessment
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Disease Activity Score (DAS)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: C reactive protein (CRP)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: RAID components (pain)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: RAID components (sleep)
Number of subjects: 248
Study: 38216296

Group type: EXPERIMENTAL
Intervention: Continuous intrafemoral thrombolysis (urokinase injection for 7 days)
Number of subjects: 195
Study: 38216319

Group type: EXPERIMENTAL
Intervention: Withdraw GC+IM (group 1)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Withdraw GC but maintain IM (group 2)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Maintain GC+IM (group 3)
Number of subjects: 146
Study: 38216351

Group type: EXPERIMENTAL
Intervention: CSF-1 (0.4% pilocarpine hydrochloride)
Number of subjects: 613

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 613
Study: 38216389

Group type: EXPERIMENTAL
Intervention: DIAGNOcam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Bitewing (BW) radiographs
Number of subjects: 60

Group type: COMPARATOR
Intervention: Temporary teeth separation
Number of subjects: 60
Study: 38216511

Group type: EXPERIMENTAL
Intervention: Flecainide (150 mg per day in a single sustained-release dose) for 6 months
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Flecainide (150 mg per day in a single sustained-release dose) for 3 months
Number of subjects: 186

Group type: COMPARATOR
Intervention: No additional treatment (standard of care) for 6 months
Number of subjects: 186
Study: 38216543

Group type: EXPERIMENTAL
Intervention: Digital platform + Community Health Worker (CHW) pairing + Usual care
Number of subjects: 50

Group type: COMPARATOR
Intervention: CHW pairing + Usual care
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Digital platform + CHW pairing + Usual care
Number of subjects: 50
Study: 38216554

Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen-expressing oncolytic measles virus derivative (MV-CEA) administered at the resection cavity (Group A)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Carcinoembryonic antigen-expressing oncolytic measles virus derivative (MV-CEA) administered intratumorally on day 1, followed by a second dose in the resection cavity on day 5 (Group B)
Number of subjects: 22
Study: 38216566

Group type: EXPERIMENTAL
Intervention: If/when-then planning prompts (standard letter)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Comparator version of the letter (control)
Number of subjects: 541
Study: 38216647

Group type: EXPERIMENTAL
Intervention: Normocaloric MUFAs-rich diet (15-20% TEE)
Number of subjects: 32
Study: 38216728

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 3225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3225
Study: 38216766

Group type: EXPERIMENTAL
Intervention: CAR T-EGFRvIII cells + pembrolizumab (anti-PD1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38216784

Group type: EXPERIMENTAL
Intervention: Gender-affirming hormone therapy for trans women
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Gender-affirming hormone therapy for trans men
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cisgender women
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cisgender men
Number of subjects: 70
Study: 38216803

Group type: EXPERIMENTAL
Intervention: Laser acupuncture
Number of subjects: 84
Study: 38216831

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 8
Study: 38216905

Group type: EXPERIMENTAL
Intervention: Class 1 (Positive class, n=169, 39%)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Class 2 (Fearful class, n=31, 7%)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Class 3 (Distressed class, n=33, 8%)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Class 4 (Hopeful class, n=202, 46%)
Number of subjects: 435
Study: 38216967

Group type: EXPERIMENTAL
Intervention: STRIDE program with foundational support
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: STRIDE program with enhanced support
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: STRIDE program
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Patient-level effectiveness outcomes
Number of subjects: 32
Study: 38216971

Group type: EXPERIMENTAL
Intervention: Mobile application (ESTOI) for asthma management with exhaustive follow-up
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Mobile application (ESTOI) for asthma management
Number of subjects: 108
Study: 38216985

Group type: COMPARATOR
Intervention: Low blood pressure target (63 mmHg)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: High blood pressure target (77 mmHg)
Number of subjects: 789

Group type: COMPARATOR
Intervention: Restrictive oxygenation target (9-10 kPa)
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Liberal oxygenation target (13-14 kPa)
Number of subjects: 789

Group type: COMPARATOR
Intervention: Device-based fever prevention for 36 hours
Number of subjects: 789

Group type: EXPERIMENTAL
Intervention: Device-based fever prevention for 72 hours
Number of subjects: 789
Study: 38217032

Group type: EXPERIMENTAL
Intervention: Upfront, early radiotherapy to ≤ 5 high-risk spine lesions plus standard-of-care systemic therapy (20-30 Gy of radiation in 2-10 fractions)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard-of-care systemic therapy
Number of subjects: 74
Study: 38217039

Group type: EXPERIMENTAL
Intervention: Urine osmolality > 760 mosmol/kg or urine creatinine > 13 mmol/L
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Days with urine output < 1 L
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Age-corrected biomarker cutoffs
Number of subjects: 20
Study: 38217343

Group type: EXPERIMENTAL
Intervention: Subendocardial viability ratio (SEVR) estimated non-invasively by analyzing the carotid pressure waveform recorded by applanation arterial tonometry.
Number of subjects: 828
Study: 38217361

Group type: EXPERIMENTAL
Intervention: LEO cohort study participants
Number of subjects: 7735
Study: 38217402

Group type: EXPERIMENTAL
Intervention: Vascular occlusion test (VOT) using near-infrared spectroscopy
Number of subjects: 120
Study: 38217481

Group type: EXPERIMENTAL
Intervention: CASA score (0-6) based on cheeks appearance scored for volume (0-3) and flaccidity (0-3) by 3 blinded evaluators.
Number of subjects: 248
Study: 38217640

Group type: EXPERIMENTAL
Intervention: Prevision hip stem
Number of subjects: 44
Study: 38217757

Group type: EXPERIMENTAL
Intervention: Mouthwash with amine + zinc lactate + fluoride system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control mouthwash
Number of subjects: 0
Study: 38217877

Group type: EXPERIMENTAL
Intervention: Very old stroke patients (80 years or older)
Number of subjects: 463
Study: 38217929

Group type: EXPERIMENTAL
Intervention: Delays in childbirth care
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High patient-to-provider ratio during antenatal care
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Delays in care decision-making and patient management
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Need for comprehensive childbirth interventions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Need for context-specific guidelines
Number of subjects: 16
Study: 38218013

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wait-list Control (WLC)
Number of subjects: 90
Study: 38218157

Group type: EXPERIMENTAL
Intervention: iMRI
Number of subjects: 321

Group type: COMPARATOR
Intervention: Control (conventional neuronavigation)
Number of subjects: 321
Study: 38218194

Group type: EXPERIMENTAL
Intervention: Fexinidazole 600 mg once daily for 10 days (6.0 g total dose)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fexinidazole 1200 mg daily for 3 days (3.6 g total)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fexinidazole 600 mg daily for 3 days followed by 1200 mg daily for 4 days (6.6 g total)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Historical placebo control group
Number of subjects: 45
Study: 38218195

Group type: EXPERIMENTAL
Intervention: 150 mg/day for 60 days (low dose group)
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: 400 mg/day for 15 days (short treatment group)
Number of subjects: 234

Group type: COMPARATOR
Intervention: 300 mg/day for 60 days (control group)
Number of subjects: 234
Study: 38218392

Group type: EXPERIMENTAL
Intervention: TAPSE/PASP ratio
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: TAPSE/PASP ≤0.33
Number of subjects: 422
Study: 38218784

Group type: EXPERIMENTAL
Intervention: Nature-based social intervention 'Friends in Nature'
Number of subjects: 316

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 316
Study: 38218843

Group type: EXPERIMENTAL
Intervention: History of diabetic foot (including ulcer/gangrene, amputation, and lower limb revascularization)
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Amputation
Number of subjects: 15773

Group type: EXPERIMENTAL
Intervention: Revascularization alone
Number of subjects: 15773
Study: 38218899

Group type: EXPERIMENTAL
Intervention: Web-based information platform (www.ich-bin-alles.de/eltern)
Number of subjects: 33
Study: 38218919

Group type: EXPERIMENTAL
Intervention: YAG laser vitreolysis (early treatment group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham laser treatment (early treatment group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: YAG laser vitreolysis (delayed treatment group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham laser treatment (delayed treatment group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: YAG laser vitreolysis
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham laser treatment
Number of subjects: 70
Study: 38218924

Group type: EXPERIMENTAL
Intervention: Low-dose quadruple antihypertensives (irbesartan 75 mg + metoprolol 23.75 mg + amlodipine 2.5 mg + indapamide 1.25 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard-dose dual antihypertensives (irbesartan 150 mg + amlodipine 5 mg)
Number of subjects: 90
Study: 38218932

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 88
Study: 38218936

Group type: EXPERIMENTAL
Intervention: telephone-delivered Common Elements Treatment Approach (t-CETA)
Number of subjects: 25
Study: 38218979

Group type: EXPERIMENTAL
Intervention: VT1021 (11.8 mg/kg, RP2D)
Number of subjects: 38
Study: 38219024

Group type: EXPERIMENTAL
Intervention: Nirsevimab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38219041

Group type: EXPERIMENTAL
Intervention: Stable short sleep group (6-hour TIB)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Variable short sleep group (8-hour, 4-hour, 8-hour, 4-hour, 6-hour TIB)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (8-hour TIB)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Stable short sleep group
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Variable short sleep group
Number of subjects: 52
Study: 38219156

Group type: EXPERIMENTAL
Intervention: Positional distraction with stabilisation exercises (Group A)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stabilisation exercises alone (Group B)
Number of subjects: 100
Study: 38219157

Group type: EXPERIMENTAL
Intervention: Muscle energy techniques (Group A)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Facet joint mobilisation (Group B)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional physical therapy (Group C)
Number of subjects: 105
Study: 38219179

Group type: EXPERIMENTAL
Intervention: Trunk stabilisation exercises
Number of subjects: 28

Group type: COMPARATOR
Intervention: Trunk activation exercises
Number of subjects: 28
Study: 38219767

Group type: EXPERIMENTAL
Intervention: Indomethacin alone
Number of subjects: 1950

Group type: COMPARATOR
Intervention: Indomethacin plus stent
Number of subjects: 1950
Study: 38219773

Group type: EXPERIMENTAL
Intervention: Revealed group (cerebroplacental ratio known)
Number of subjects: 9492

Group type: COMPARATOR
Intervention: Concealed group (cerebroplacental ratio unknown)
Number of subjects: 9492
Study: 38219864

Group type: EXPERIMENTAL
Intervention: Cumulative dietary fiber intake (assessed as area under the curve for energy-adjusted fiber intake from age 0-26 years)
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Cumulative dietary fiber intake
Number of subjects: 357
Study: 38220413

Group type: EXPERIMENTAL
Intervention: Curcumin (three capsules of 500 mg of Curcuma longa extract, with 98.42 % total curcuminoids) for twelve weeks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (three capsules of 500 mg of starch) for twelve weeks
Number of subjects: 48
Study: 38220592

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance exercise + cognitive training (CARE+CT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Stretching exercise + cognitive training (SE+CT)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups (CARE+CT and SE+CT)
Number of subjects: 72
Study: 38221545

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 436
Study: 38221601

Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy-Emotion Development (PCIT-ED)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Online parenting education
Number of subjects: 62
Study: 38221808

Group type: EXPERIMENTAL
Intervention: 4 mg hydromorphone (Day 2)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 0 mg, 2 mg and 8 mg hydromorphone (Days 3-5)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 100
Study: 38222041

Group type: EXPERIMENTAL
Intervention: Emicizumab Prophylaxis
Number of subjects: 0
Study: 38222040

Group type: EXPERIMENTAL
Intervention: Risk scores for thromboprophylaxis
Number of subjects: 0
Study: 38222057

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) program within <2 years post-radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise training (ET) program between 2 to 5 years post-radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine post-radiotherapy care including ET program
Number of subjects: 0
Study: 38222092

Group type: EXPERIMENTAL
Intervention: Health Behavior group (HB) - Remote coaching on diet, moderate-intensity walking, and breathing exercises
Number of subjects: 44
Study: 38222095

Group type: EXPERIMENTAL
Intervention: Standardised limited echo protocol
Number of subjects: 0
Study: 38222252

Group type: EXPERIMENTAL
Intervention: COOL-AF scores in APHRS
Number of subjects: 3628

Group type: COMPARATOR
Intervention: CHA scores
Number of subjects: 3628
Study: 38222256

Group type: EXPERIMENTAL
Intervention: Patients without SMuRFs
Number of subjects: 10775

Group type: COMPARATOR
Intervention: Patients with SMuRFs
Number of subjects: 10775
Study: 38222312

Group type: EXPERIMENTAL
Intervention: Lymphodepletion therapy consisting of cyclophosphamide (30mg/kg) for 2 days followed by Fludarabine (25mg/m2) and TILs infusion.
Number of subjects: 2
Study: 38222876

Group type: EXPERIMENTAL
Intervention: Islamic Trauma Healing (ITH) intervention, a 6-session manualized mosque-based, lay-led group intervention combining Islamic principles with exposure and cognitive restructuring for PTSD.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Delayed (waitlist; WL) ITH condition (control group).
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Islamic Trauma Healing (ITH) intervention.
Number of subjects: 200
Study: 38223663

Group type: EXPERIMENTAL
Intervention: Tetanic stimulus applied to the ulnar nerve
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tetanic stimulus applied to the medial side of the tibia
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tetanic stimulus applied to the thorax (T5 dermatome)
Number of subjects: 12
Study: 38224135

Group type: COMPARATOR
Intervention: Testosterone replacement therapy (TRT)
Number of subjects: 11419
Study: 38224415

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 94

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 94
Study: 38224478

Group type: EXPERIMENTAL
Intervention: OCH-NCNP1 (3.0 mg, orally administered once weekly for 24 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: OCH-NCNP1
Number of subjects: 30
Study: 38224564

Group type: EXPERIMENTAL
Intervention: Next-generation multi-target stool DNA (mt-sDNA) test
Number of subjects: 232
Study: 38224591

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 126

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study: 38224663

Group type: EXPERIMENTAL
Intervention: Definitive chemoradiation with a dose of 50.4 Gy in 28 fractions and a concomitant boost of 62 Gy in 28 fractions to the primary target volume (CTV-/PTV-T)
Number of subjects: 108
Study: 38224706

Group type: EXPERIMENTAL
Intervention: IPTp with dihydroartemisinin-piperaquine plus daily co-trimoxazole
Number of subjects: 666

Group type: COMPARATOR
Intervention: Placebo plus daily co-trimoxazole
Number of subjects: 666
Study: 38224710

Group type: EXPERIMENTAL
Intervention: Daily co-trimoxazole plus monthly dihydroartemisinin-piperaquine (3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for 3 days)
Number of subjects: 904

Group type: COMPARATOR
Intervention: Daily co-trimoxazole plus monthly placebo
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Daily co-trimoxazole plus monthly dihydroartemisinin-piperaquine
Number of subjects: 904
Study: 38224916

Group type: EXPERIMENTAL
Intervention: MR-guided stereotactic ablative radiotherapy (SABR) with fractionation schemes of 45-67.5 Gy in 3-8 fractions
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: MR-guided stereotactic ablative radiotherapy (SABR)
Number of subjects: 121
Study: 38225549

Group type: EXPERIMENTAL
Intervention: nabiximols in combination with TMZ
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo in combination with TMZ
Number of subjects: 0
Study: 38225551

Group type: EXPERIMENTAL
Intervention: One-year supervised physical activity program
Number of subjects: 236
Study: 38225561

Group type: EXPERIMENTAL
Intervention: Strengthening the brain - a lifestyle intervention combining personal fitness, mental coaching, dietary advice, and cognitive training
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Strengthening the mind - a work-focused intervention combining the capability approach and the participatory approach in one-on-one coaching by trained work coaches who have MS themselves
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control group - receiving general information about cognitive impairment in MS and receiving care as usual
Number of subjects: 270